Skip to main content

Maetzold Derek J's Form 4 filing

Castle Biosciences Inc (CSTL) · filed Sep 15, 2021

Accession no.
0001447362-21-000221
Filed
Sep 15, 2021
Trade date
Sep 14, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions. Open-market sales total $247.9K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maetzold Derek JCIK 0001239501Director, Officer (Pres. & Chief Exec. Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 14, 2021Common StockSSaleDisposed−781$73.36F2−$57,294.16161,852Indirect
Sep 14, 2021Common StockSSaleDisposed−472$74.65F5−$35,234.8161,380Indirect
Sep 14, 2021Common StockSSaleDisposed−227$75.69F6−$17,181.63161,153Indirect
Sep 14, 2021Common StockSSaleDisposed−186$76.43F7−$14,215.98160,967Indirect
Sep 14, 2021Common StockSSaleDisposed−781$73.36F2−$57,294.16149,251Indirect
Sep 14, 2021Common StockSSaleDisposed−473$74.65F5−$35,309.45148,778Indirect
Sep 14, 2021Common StockSSaleDisposed−227$75.69F6−$17,181.63148,551Indirect
Sep 14, 2021Common StockSSaleDisposed−186$76.43F7−$14,215.98148,365Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $73.050 to $73.940, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 2 transactions in Table I.

F5

This transaction was executed in multiple trades at prices ranging from $74.100 to $75.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 2 transactions in Table I.

F6

This transaction was executed in multiple trades at prices ranging from $75.105 to $76.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 2 transactions in Table I.

F7

This transaction was executed in multiple trades at prices ranging from $76.300 to $76.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)